These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24670306)

  • 1. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?
    Romero-Ramos M; von Euler Chelpin M; Sanchez-Guajardo V
    Hum Vaccin Immunother; 2014; 10(4):852-67. PubMed ID: 24670306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
    Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
    J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.
    Christiansen JR; Olesen MN; Otzen DE; Romero-Ramos M; Sanchez-Guajardo V
    J Neuroinflammation; 2016 Apr; 13(1):74. PubMed ID: 27055651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on immunity and inflammation in Parkinson disease pathology.
    Joshi N; Singh S
    J Neurosci Res; 2018 Mar; 96(3):379-390. PubMed ID: 29072332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination strategies in tauopathies and synucleinopathies.
    Braczynski AK; Schulz JB; Bach JP
    J Neurochem; 2017 Dec; 143(5):467-488. PubMed ID: 28869766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.
    Grozdanov V; Bousset L; Hoffmeister M; Bliederhaeuser C; Meier C; Madiona K; Pieri L; Kiechle M; McLean PJ; Kassubek J; Behrends C; Ludolph AC; Weishaupt JH; Melki R; Danzer KM
    Ann Neurol; 2019 Oct; 86(4):593-606. PubMed ID: 31343083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
    Gardai SJ; Mao W; Schüle B; Babcock M; Schoebel S; Lorenzana C; Alexander J; Kim S; Glick H; Hilton K; Fitzgerald JK; Buttini M; Chiou SS; McConlogue L; Anderson JP; Schenk DB; Bard F; Langston JW; Yednock T; Johnston JA
    PLoS One; 2013; 8(8):e71634. PubMed ID: 24058406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease.
    Kustrimovic N; Marino F; Cosentino M
    Curr Med Chem; 2019; 26(20):3719-3753. PubMed ID: 30306855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Gallups NJ; Standaert DG; Harms AS
    Brain; 2021 Aug; 144(7):2047-2059. PubMed ID: 33704423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
    Olson KE; Gendelman HE
    Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the immune system for the treatment of Parkinson's disease.
    Vedam-Mai V
    Brain Res; 2021 May; 1758():147308. PubMed ID: 33524380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
    Thome AD; Standaert DG; Harms AS
    PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization strategies for Parkinson's disease.
    Ha D; Stone DK; Mosley RL; Gendelman HE
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S218-21. PubMed ID: 22166440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans.
    Kuwahara T; Koyama A; Gengyo-Ando K; Masuda M; Kowa H; Tsunoda M; Mitani S; Iwatsubo T
    J Biol Chem; 2006 Jan; 281(1):334-40. PubMed ID: 16260788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
    Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
    Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Blood Monocyte Functions in Parkinson's Disease.
    Nissen SK; Shrivastava K; Schulte C; Otzen DE; Goldeck D; Berg D; Møller HJ; Maetzler W; Romero-Ramos M
    Mov Disord; 2019 Nov; 34(11):1711-1721. PubMed ID: 31449711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.